press release- (OVA1 test) Vermillion to Host Conference Call to Present Company Update and Review Financial Results May 10th, 2011

BJC - Abstract - Predictors of contralateral breast cancer in BRCA1 and Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers (stage 1/11 breast cancer/mutation carriers)

Purpose:

The objective of this study was to estimate the risk of contralateral breast cancer in BRCA1 and BRCA2 carriers; and measure the extent to which host, family history, and cancer t

Conclusion:

The risk of contralateral breast cancer risk in BRCA mutation carriers declines with the age of diagnosis and increases with the number of first-degree relatives affected with breast cancer. Oophorectomy reduces the risk of contralateral breast cancer in young women with a BRCA mutation.

BJC - Abstract: Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis

Results:

  The five studies included 47 325 SLE patients (42 171 females) observed for 282 553 patient years. There were 376 breast cancers, 66 endometrial cancers, and 44 ovarian cancers. The total number of cancers observed was less than that expected, with SIRs of 0.76 (95% CI: 0.69, 0.85) for breast cancer, 0.71 (95% CI: 0.55, 0.91) for endometrial cancer, and 0.66 (95% CI: 0.49, 0.90) for ovarian cancer.

Conclusions:

  Data strongly support a decreased risk of breast, ovarian, and endometrial cancers in SLE. This may be due to inherent differences in women in SLE (vs the general population) regarding endogenous oestrogen, other medications, and/or genetic make-up.

Oncology - Interpreting Clinical Trial Results - Clinical Options in Practice

Note: requires registration (free); worth reading

Oncology - Interpreting Clinical Trial Results

Authors: Maurie Markman, MD (More Info)

Released: 11/17/10

Last Reviewed: 12/1/10